Shares of EDGE MEDICAL-B (02675) experienced a significant surge of over 13% during the morning trading session.

As of the latest update, the stock was up 13.37% to HK$41.38, with a trading turnover of HK$21.79 million.

The catalyst for this upward movement is recent company news regarding its expansion into the Australian market.

According to an official announcement, the company's self-developed surgical robot systems have successfully received regulatory approval from Australia's Therapeutic Goods Administration.

The approved products include the Edge Multi-Port Laparoscopic Surgical Robot MP1000, the Edge Single-Port Laparoscopic Surgical Robot SP1000, and the integrated Edge Multi/Single-Port Surgical Robot Super System MSP2000.

All three platforms have been officially listed on the Australian Register of Therapeutic Goods.

These approved robotic systems are indicated for endoscopic surgical procedures across multiple specialties, including urology, gynecology, general surgery, and thoracic surgery.

This regulatory milestone signifies formal market access for the company's comprehensive portfolio of multi-port, single-port, and integrated surgical robot platforms in Australia.

It establishes a crucial foundation for the company's strategy to further develop its presence in the Australian and broader Asia-Pacific markets.

Furthermore, this achievement represents a significant step in advancing the global clinical application of domestically developed, high-end surgical robotic technology.